PDRN Clinical Evidence (2026): Mechanism, Wound Healing and Skin Research Reviewed

Quick answer

PDRN (polydeoxyribonucleotide) is a mixture of DNA fragments, usually purified from salmon or trout sperm. In laboratory work it is thought to act mainly through the adenosine A2A receptor and by supplying nucleotide "building blocks" through the salvage pathway. Its strongest human evidence comes from injected PDRN in wound care, such as a 216-patient randomised trial in diabetic foot ulcers. Evidence for skincare you apply at home is much thinner and specific to each formula.

Independent educational content. This page summarises research; it is not medical advice.

In this guide

• The evidence at a glance
• What is PDRN?
• How PDRN is thought to work
• Wound healing: the strongest human evidence
• Dermatology and aesthetics
• Beyond skin: other research areas
• What the evidence does not show
• Safety in the research
• Frequently asked questions
• Where to go next
• References

The evidence at a glance

What is PDRN?

PDRN stands for polydeoxyribonucleotide: chains of DNA building blocks (deoxyribonucleotides) cut to a range of sizes. Reviews usually describe pharmaceutical PDRN as DNA fragments of roughly 50 to 1,500 kDa, extracted mainly from salmon, with a purity above 95% [3][11].

PDRN is closely related to PN (polynucleotides), which are longer DNA chains. The two words are often used interchangeably, which causes confusion. A 2025 review proposed reserving "PDRN" for chains under 1,500 kDa and "PN" for longer chains [2]. A separate 2025 review argues that the two behave differently: PN mainly as a scaffold that supports the skin matrix, PDRN mainly through receptor signalling [4].

PDRN was first developed as a medicine. In Italy and South Korea, injectable PDRN products have long been used in wound care and tissue repair. In skincare it appears on ingredient lists as Sodium DNA or "PDRN". For a plain-English introduction, see our PDRN guide.

How PDRN is thought to work

Reviews published between 2021 and 2026 agree on two main mechanisms [3][4][12]:

1. Adenosine A2A receptor activation. PDRN fragments act on the A2A receptor, which is linked to reduced release of inflammatory messengers (such as TNF-α, IL-6 and IL-1β) and increased VEGF, a signal for new blood-vessel growth.
2. The salvage pathway. As the DNA breaks down, it releases nucleotides and nucleosides that cells can reuse to make new DNA. In principle, this saves cells energy when they are dividing quickly during repair.

Laboratory and animal studies also report more collagen production, more fibroblast and keratinocyte activity and less cell death [3][12].

Important caveat: most of this mechanistic work comes from cells, animals and injected PDRN. It explains why PDRN is biologically interesting. It does not prove that a cream reaches the cells where these effects happen. We cover that question in Does topical PDRN work?

Wound healing: the strongest human evidence

The best-known trial is a randomised, double-blind, placebo-controlled study at two Italian centres [1]. It involved 216 people with diabetes and hard-to-heal foot ulcers (Wagner grade 1 or 2). PDRN or placebo was given by intramuscular and perilesional injection for 8 weeks.

• Complete healing: 37.3% with PDRN vs 18.9% with placebo.
• Median time to complete healing: 30 days vs 49 days.
• Median healed (re-epithelialised) area: 82.2% vs 49.3%.

A smaller 2017 randomised trial (20 patients) reported better tissue oxygen levels and more new blood vessels in diabetic foot ulcers treated with PDRN injections [5].

A 2020 systematic review of 34 studies (laboratory, animal and clinical) concluded that PDRN consistently supported tissue repair through the salvage pathway and the A2A receptor [6].

How to read this: these results are for injected pharmaceutical PDRN in medical wound care, given under clinical supervision. They are the reason PDRN is taken seriously. They are not evidence about a skincare product.

Dermatology and aesthetics

Polynucleotide injections

A systematic review registered on PROSPERO and led by Imperial College London (published December 2024, in the 2025 volume of the Journal of Cosmetic Dermatology) found nine studies of low or moderate quality involving 219 patients [7]. Polynucleotide injections were linked with fewer wrinkles, better texture and better elasticity. Side effects were generally mild and short-lived. The authors said that rigorous, high-quality studies are still needed and that there is little agreement on how best to use them.

After lasers, peels and microneedling

A 2026 narrative review looked at PDRN as an add-on after aesthetic procedures [8]. It describes human studies, including RCTs and split-face trials, in which PDRN was linked with faster re-epithelialisation and less redness, scarring and pigmentation. The authors also list the limitations: few RCTs in aesthetic patients, small samples, varied formulations and little long-term follow-up.

Topical (leave-on) products

The topical evidence is the newest and the thinnest:

• A 2026 study of a 0.1% medium-length PDRN eye cream combined laboratory, ex vivo and imaging work with a 28-day randomised, double-blind, split-face trial against 0.1% retinol. It reported about twice the improvement in periocular wrinkles and dermal measures compared with retinol [9]. Several authors work for companies that develop the ingredient, and the study used one proprietary formula.
• A 2025 study of a low-molecular-weight plant (peony) PDRN reported reduced water loss after 2 weeks in a skin-irritation model and better eye-area elasticity after 4 weeks, in a small group (n = 10) [10].

Neither study shows that PDRN products in general work this way. Each result applies to the formula that was tested.

Beyond skin: other research areas

Most PDRN research is not about skin at all. Recent reviews cover tendon disorders [13], osteoarthritis [14], musculoskeletal pain and dentistry. This breadth shows how actively PDRN is being studied. It also explains why its general reputation can run ahead of the evidence for skincare.

What the evidence does not show

Safety in the research

Across wound, injectable and aesthetic studies, reported side effects are generally mild and short-lived. These include injection-site pain, redness or swelling for injected products [1][7][8]. Topical products are cosmetics, so most reactions come from the whole formula (fragrance, preservatives, other actives) rather than PDRN alone. People with fish allergy should check the source and ask a pharmacist or GP if their allergy is severe. Pregnancy data for cosmetic PDRN are limited.

Frequently asked questions

Is there good clinical evidence for PDRN?

Yes, for some medical uses of injected PDRN, especially diabetic foot ulcers, where a 216-patient randomised placebo-controlled trial found faster and more frequent healing [1]. For skincare, the evidence is early and specific to each formula.

How does PDRN work on skin?

It is thought to activate the adenosine A2A receptor, which reduces inflammatory signalling and supports blood-vessel growth and collagen production. Its fragments may also supply nucleotides through the salvage pathway. These mechanisms come mainly from laboratory and injection research [3][4].

Is PDRN the same as polynucleotides (PN)?

They are related DNA-derived ingredients, but PN chains are longer. A 2025 review proposed 1,500 kDa as the dividing line [2]. Clinic "polynucleotide" injections often contain PN, PDRN or both.

Does PDRN skincare have clinical trials?

A small number of trials exist for specific formulas, such as a 28-day split-face eye-cream study published in 2026 [9]. They are short, often industry-linked, and do not apply to other products.

What are the gaps in PDRN research?

Few large independent trials, inconsistent definitions of PDRN vs PN, little long-term follow-up, and a lack of studies comparing topical formulas with placebo [2][7][8].

Where to go next

• Does topical PDRN work? Molecular weight and skin penetration
• PDRN and polynucleotides in the UK: the rules explained
• PDRN in the UK, 2026: salmon vs plant PDRN
• Are PDRN injections safe?
• PDRN skincare vs salmon DNA facials
• PDRN ingredient card

References

1. Squadrito F, Bitto A, Altavilla D, et al. The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: results of a clinical trial. J Clin Endocrinol Metab. 2014. DOI · PubMed

2. Marques C, Porcello A, Cerrano M, et al. From Polydeoxyribonucleotides (PDRNs) to Polynucleotides (PNs): Bridging the Gap Between Scientific Definitions, Molecular Insights, and Clinical Applications. Biomolecules. 2025. DOI · PubMed

3. Kim TH, Heo SY, Oh GW, et al. Applications of Marine Organism-Derived Polydeoxyribonucleotide: Its Potential in Biomedical Engineering. Mar Drugs. 2021. DOI · PubMed

4. Kim. Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives. Pharmaceutics. 2025. DOI · PubMed

5. Kim S, Kim J, Choi J, et al. Polydeoxyribonucleotide Improves Peripheral Tissue Oxygenation and Accelerates Angiogenesis in Diabetic Foot Ulcers. Arch Plast Surg. 2017. DOI · PubMed

6. Colangelo MT, Galli C, Guizzardi S. The effects of polydeoxyribonucleotide on wound healing and tissue regeneration: a systematic review of the literature. Regen Med. 2020. DOI · PubMed

7. Lampridou S, Bassett S, Cavallini M, Christopoulos G. The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review. J Cosmet Dermatol. 2025;24(2):e16721. DOI · PubMed

8. Flores Rodríguez, Toledo Avelar, Yi, et al. Polydeoxyribonucleotide (PDRN) in Post-procedure Recovery in Aesthetic Medicine: A Narrative Review. Cureus. 2026. DOI · PubMed

9. Ye R, Wang Q, Du L, Li L, Hu F, et al. Topical medium-length PDRN enhances dermal extracellular matrix repair in photodamaged skin via PI3K-Akt/TGF-β-regulated pathways. PLoS One. 2026;21(7):e0350905. DOI · PubMed

10. Bak, Jung, et al. Anti-Aging Efficacy of Low-Molecular-Weight Polydeoxyribonucleotide Derived from Paeonia lactiflora. Int J Mol Sci. 2025. DOI · PubMed

11. Nguyen, Wang, Nguyen, et al. Recent advances on polydeoxyribonucleotide extraction and its novel application in cosmeceuticals. Int J Biol Macromol. 2024. DOI · PubMed

12. Galeano M, Pallio G, Irrera N, et al. Polydeoxyribonucleotide: A Promising Biological Platform to Accelerate Impaired Skin Wound Healing. Pharmaceuticals. 2021. DOI · PubMed

13. Luo, Huang, Li, et al. Review of Preclinical and Clinical Studies Supporting the Role of Polydeoxyribonucleotide in the Treatment of Tendon Disorders. Med Sci Monit. 2025. DOI · PubMed

14. Baek. Polydeoxyribonucleotide (PDRN) in Osteoarthritis: Immunomodulatory and Matrix-Supportive Potential, A2A Receptor-Associated Mechanisms, and Translational Challenges. Medicina. 2026. DOI · PubMed

15. Kim, Lee, et al. Plant-Derived Polynucleotides/Polydeoxyribonucleotides in Skin Biomaterials: Delivery Platforms and Bioactivity Attribution. J Funct Biomater. 2026. DOI · PubMed